Law360, New York (March 12, 2010, 6:49 PM ET) -- IntelliPharmaCeutics Corp. has struck a settlement in Elan Pharma International Ltd.'s patent infringement suit over a generic version of attention deficit hyperactivity disorder drug Focalin XR.
The parties filed a request for a 45-day stay Thursday in the U.S. District Court for the District of Delaware to allow for review of the settlement, which would end the suit against IntelliPharmaCeutics over two Elan-held patents.
The agreement comes just a few days after the District of New Jersey signed off on IntelliPharmaCeutics' settlement with Novartis Pharmaceuticals Corp....
IntelliPharmaCeutics, Elan Settle Focalin Patent Spat
To view the full article, take a free trial now.
